US 12,071,473 B2
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
Randolph J. Noelle, Plainfield, NH (US); Sabrina Ceeraz, Lebanon, NH (US); Isabelle LeMercier, Enfield, NH (US); Elizabeth Nowak, West Lebanon, NH (US); and Janet Lines, London (GB)
Assigned to THE TRUSTEES OF DARMOUTH COLLEGE, Hanover, NH (US); and KING'S COLLEGE LONDON, London (GB)
Filed by THE TRUSTEES OF DARTMOUTH COLLEGE, Hanover, NH (US); and KING'S COLLEGE LONDON, London (GB)
Filed on Mar. 16, 2020, as Appl. No. 16/820,116.
Application 16/820,116 is a division of application No. 13/925,094, filed on Jun. 24, 2013, granted, now 10,745,467.
Application 13/925,094 is a continuation in part of application No. 13/637,381, granted, now 9,631,018, issued on Apr. 25, 2017, previously published as PCT/US2011/030087, filed on Mar. 25, 2011.
Application 13/637,381 is a continuation in part of application No. 12/732,371, filed on Mar. 26, 2010, granted, now 8,231,872, issued on Jul. 31, 2012.
Claims priority of provisional application 61/663,969, filed on Jun. 25, 2012.
Claims priority of provisional application 61/663,431, filed on Jun. 22, 2012.
Claims priority of provisional application 61/449,882, filed on Mar. 7, 2011.
Claims priority of provisional application 61/436,379, filed on Jan. 26, 2011.
Claims priority of provisional application 61/390,434, filed on Oct. 6, 2010.
Prior Publication US 2021/0032317 A1, Feb. 4, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/705 (2006.01); A61K 38/17 (2006.01); A61K 38/21 (2006.01); A61K 39/395 (2006.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/18 (2013.01) [A61K 38/21 (2013.01); A61K 38/212 (2013.01); A61K 38/215 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); C07K 14/70503 (2013.01); C07K 16/2827 (2013.01); C07K 16/30 (2013.01); A61K 2039/505 (2013.01); C07K 2317/76 (2013.01); C07K 2319/00 (2013.01); C07K 2319/30 (2013.01); Y02A 50/30 (2018.01)] 20 Claims
 
1. An isolated V-region Immunoglobulin-containing Suppressor of T cell Activation (“VISTA”) fusion protein comprising a polypeptide with at least about 90% sequence identity to the polypeptide sequence of SEQ ID NO: 2 or 4 and further comprising at least one immunoglobulin (Ig) Fc or constant region.